June 8, 2020 / 2:02 PM / a month ago

BRIEF-Kiniksa Announces Data From Mavrilimumab Treatment Protocol In Severe COVID-19 Pneumonia And Active U.S. IND For Phase 2/3 Clinical Trial

June 8 (Reuters) - Kiniksa Pharmaceuticals Ltd:

* KINIKSA ANNOUNCES 28-DAY CLINICAL OUTCOMES DATA FROM MAVRILIMUMAB TREATMENT PROTOCOL IN SEVERE COVID-19 PNEUMONIA AND ACTIVE U.S. IND FOR PHASE 2/3 CLINICAL TRIAL

* KINIKSA - ANNOUNCED ACTIVE IND WITH U.S. FDA FOR GLOBAL PLACEBO-CONTROLLED PHASE 2/3 CLINICAL TRIAL OF MAVRILIMUMAB IN SEVERE COVID-19 PNEUMONIA, HYPERINFLAMMATION

* KINIKSA - OVER 28-DAY FOLLOW-UP PERIOD, MAVRILIMUMAB-TREATED PATIENTS EXPERIENCED EARLIER & IMPROVED CLINICAL OUTCOMES THAN CONTROL-GROUP PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below